Clinical Report: Evaluating the Clinical Significance of Predictive Models for Gastric Function and Organic Lesions
Overview
This study evaluates the clinical value of predictive models for gastric function and organic lesions using data from 1,677 patients.
Background
Gastric cancer remains a significant health concern, particularly in regions with high incidence rates like China. Early detection and intervention are crucial for improving outcomes, yet traditional screening methods face limitations.
Data Highlights
Model
Sensitivity
Specificity
Positive Predictive Value
Negative Predictive Value
AUC
Youden Index
Gastric Function Prediction Model
91.16%
39.18%
83.27%
57.14%
0.702
0.303
Gastric Organic Lesion Prediction Model
89.55%
33.22%
70.86%
63.67%
0.672
0.228
Key Findings
The gastric function prediction model achieved a sensitivity of 91.16% and specificity of 39.18%. The gastric organic lesion prediction model had a sensitivity of 89.55% and specificity of 33.22%. Both models demonstrated good predictive performance with AUC values of 0.702 and 0.672, respectively.
Clinical Implications
The findings indicate the predictive models' potential in identifying gastric function abnormalities and organic lesions.
Conclusion
The study validates the predictive models for gastric function and organic lesions.
The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement
